Invex Therapeutics Ltd (ASX: IXC) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Invex Therapeutics Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $5.56 million
P/E Ratio N/A
Dividend Yield 262.39%
Shares Outstanding 75.15 million
Earnings per share -0.080
Dividend per share 0.19
Year To Date Return -12.35%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Invex Therapeutics Ltd (ASX: IXC)
    Latest News

    Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
    Share Gainers

    This ASX healthcare company just got FDA approval, and its share price is soaring 18%

    Invex Therapeutics is exciting the market today after announcing some big news.

    Read more »

    IXC ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Invex Therapeutics Ltd

    Invex Therapeutics Ltd is a biopharmaceutical company, focused on the research and development of Exenatide as a treatment for neurological conditions such as Idiopathic Intracranial Hypertension (IIH), traumatic brain injury, or acute stroke. Its other program under development is Presendin which can be used for disabling headaches and permanent vision loss in females. Geographically, it operates only in Australia.

    IXC Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    20 Jun 2024 $0.07 $0.00 0.00% 59,368 $0.07 $0.07 $0.07
    19 Jun 2024 $0.07 $0.00 0.00% 312,855 $0.07 $0.07 $0.07
    18 Jun 2024 $0.07 $0.00 0.00% 95,153 $0.07 $0.07 $0.07
    17 Jun 2024 $0.07 $0.00 0.00% 2,528 $0.07 $0.07 $0.07
    14 Jun 2024 $0.07 $0.00 0.00% 168,250 $0.07 $0.07 $0.07
    13 Jun 2024 $0.07 $0.00 0.00% 49,068 $0.07 $0.07 $0.07
    12 Jun 2024 $0.07 $0.00 0.00% 180,000 $0.07 $0.07 $0.07
    11 Jun 2024 $0.07 $-0.01 -12.82% 49,626 $0.07 $0.07 $0.07
    07 Jun 2024 $0.08 $0.02 33.33% 182,550 $0.07 $0.08 $0.07
    06 Jun 2024 $0.06 $-0.02 -25.64% 83,219 $0.07 $0.07 $0.06
    05 Jun 2024 $0.08 $0.00 0.00% 210 $0.08 $0.08 $0.08
    04 Jun 2024 $0.08 $0.00 0.00% 68,200 $0.08 $0.08 $0.08
    03 Jun 2024 $0.08 $0.00 0.00% 6,321 $0.08 $0.08 $0.08
    31 May 2024 $0.08 $0.00 0.00% 164,532 $0.08 $0.08 $0.08
    30 May 2024 $0.08 $-0.01 -11.90% 31,478 $0.08 $0.08 $0.08

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    09 Apr 2024 Megan Baldwin Cancelled 400,000 $33,600
    As advised by the company. Cancellation of unlisted options
    27 Mar 2024 Thomas (Tom) Duthy Transfer 285,661 $21,424
    Off-market transfer.
    27 Mar 2024 Thomas (Tom) Duthy Transfer 285,661 $21,424
    Off-market transfer.
    10 Nov 2023 Megan Baldwin Cancelled 100,000 $22,500
    As advised by the company. Cancellation of unlisted options
    24 Aug 2023 Thomas (Tom) Duthy Buy 178,738 $32,172
    On-market trade.

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr David McAuliffe Non-Executive Director Mar 2019
    Mr McAuliffe is a company director and entrepreneur who has had over 24 years of experience, mostly in the international biotechnology field. During that time, he was involved in numerous capital raisings and in-licensing of technologies. He is a founder of several companies in Australia, France, and the United Kingdom, many of which have become public companies.
    Mrs Narelle Warren Chief Financial OfficerCompany Secretary Mar 2019
    Ms Warren has over twenty years of corporate advisory, financial management and company secretarial experience. Ms Warren has coordinated and assisted in corporate transactions, including acquisitions, divestments and raising funds via private and public equity markets.
    Mr David Colin Wheeler Non-Executive Director Nov 2023
    David has more than 30 years of Senior Executive Management, Directorships, and Corporate Advisory experience. He is a foundation Director and Partner of Pathways Corporate a boutique Corporate Advisory firm that undertakes assignments on behalf of family offices, private clients, and ASX listed companies. David is a Fellow of the Australian Institute of Company Directors (FAICD). He is currently Non-Executive Chairman of Protean Energy Ltd, PVW Resources Ltd and Avira Resources Ltd and a Non-Executive Director of Ragnar Metals Ltd, Tyranna Resources Ltd, MOAB Ltd, Cycliq Group Ltd, Cradle Resources Ltd and OZZ Resources Ltd.
    Dr Megan Baldwin Non-Executive Director Feb 2021
    Dr Baldwin is currently over-seeing the expansion of the company's management team in the U.S. and preparing for commercialization of OPT-302. Dr Baldwin is a biotechnology executive, having over 20 years of experience working on therapeutic drug development programs for cancer and ophthalmic indications. Prior to Opthea, Dr Baldwin was employed at Genentech (now Roche) as a postdoctoral researcher before moving to Genentech's commercial division. Dr Baldwin also serves on the Board of Ausbiotech as Deputy Chair. Dr Baldwin is considered an independent Director.
    Dr Thomas (Tom) Duthy Executive Director Oct 2020
    Dr Duthy has over 18 years of direct financial market and executive level/Board experience with ASX listed companies. He is a Director and Founder of Nemean Group, which provides corporate advisory and investor relations (IR) services in the Life Sciences and Technology sectors. Prior to Sirtex, Tom spent ten years as a leading sell-side Healthcare & Biotechnology analyst at Taylor Collison Limited, focused mainly on small cap companies.
    Carol Parish Chief Operating Officer
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Tattarang 8,846,154 11.77%
    Tisia Nominees Pty Ltd <Henderson Family A/C> 3,725,000 4.96%
    Mr Jason Loveridge 3,374,462 4.49%
    Mr David Jerimiah Mcauliffe 3,350,001 4.46%
    Jk Nominees Pty Ltd <The Jk Fund A/C> 3,000,000 3.99%
    Prof Alexandra Jean Sinclair 2,500,000 3.33%
    Mrs Kathryn Salkilld 2,293,000 3.05%
    The University Of Birmingham 2,000,000 2.66%
    Bannaby Investments Pty Limited<Bannaby Super Fund A/C> 1,625,000 2.16%
    Sunset Capital Management Pty Ltd<Sunset Superfund A/C> 1,448,175 1.93%
    Anthony Grist 1,338,518 1.78%
    Cityscape Asset Pty Ltd<Cityscape Family A/C> 1,150,000 1.53%
    Cabletime Pty Ltd <Ingodwe A/C> 1,120,000 1.49%
    Sandhurst Trustees Ltd<Collins St Value Fund A/C> 1,081,924 1.44%
    Palla Nominees Pty Ltd <P C Blackman S/F No 2 A/C> 580,000 0.77%
    Ardroy Securities Pty Ltd<Cameron Investment Unit A/C> 550,407 0.72%
    Endless Summer (Wa) Pty Ltd<Peter Nelson Super Fund A/C> 550,000 0.73%
    Ms Sophie Alice Loveridge 493,000 0.66%
    Peter Kyros Pty Ltd <Kyros Sf A/C> 470,075 0.63%
    Webinvest Pty Ltd<Olsb Unit A/C> 375,000 0.50%

    Profile

    since

    Note